Topic summary

IGF-1 as a surrogate endpoint and its limitations — the long version

Compounds › Secretagogues & GH axis CJC-1295 observational data ipamorelin needs a source Solved Closed

This is a generated summary. It shows the 5 most-liked posts from a topic of 19, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

k.batistaTL2 Moderator20 May 2025#4

On the opening post — agreed on the reasoning, with one qualification.

What a well-designed human trial of a secretagogue would look like: randomised, placebo-controlled, adequate sample size, IGF-1 as primary outcome, muscle and strength as secondary outcomes, adequate follow-up duration. Very few secretagogue trials meet that description.

22 likes 14mo

dexa_twice_yearlyTL3Regular Solution8 Jun 2025#7

crossover_review, post #3: post #2 answers the question as asked. The question underneath it is different. I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this,… Go to post

post #6 is right about the mechanism and I think understates the practical bit.

Pulsatile secretion matters because growth hormone is secreted in pulses, not continuously. A single post-dose growth hormone level is nearly uninterpretable. Assessing this class properly requires serial sampling or an integrated measure like IGF-1, and almost nothing published online does either.

6 likes in reply to #3 14mo

IMainwaringTL3Regular20 Jun 2025#9

Picking up post #6: that is the part I would want checked first.

Secretagogues and glucose tolerance: there is a mechanistic concern that sustained growth hormone elevation might impair glucose tolerance. The clinical relevance of this concern in practice is not well established.

31 likes 13mo

r.chukwuTL2 Moderator21 Jul 2025#15

n.osei, post #1: On the subject in the title: IGF-1 as a surrogate endpoint and its limitations — the long version Working notes rather than a conclusion. I have seen STEP 2 ( Lancet , 2021) cited in support of a claim I do not think it supports, twice this month, so I would like to work through what it actually shows. My reading is that the trial is… Go to post

Worth separating two things that post #11 runs together.

Development history is more informative than speculation: ipamorelin was investigated clinically for post-operative ileus and was not taken forward to registration. That it was not brought to market tells you something about the cost-benefit calculation that any amount of forum enthusiasm does not.

17 likes in reply to #1 12mo

BramleyTL2Member5 Aug 2025#18

Reading a rodent study on a secretagogue without over-extrapolating: rodent studies can show a mechanism is plausible. They cannot show magnitude of effect in humans or safety profile in humans. That gap is larger for secretagogues than for incretin agonists because the human evidence is thinner.

33 likes 12mo

Read the full topic (19 posts)

This topic was closed 60 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.

Suggested topics

Topic	Participants	Replies	Views	Activity
About the Secretagogues & GH axis category Compounds › Secretagogues & GH axis GHRP class CJC-1295 ipamorelin Pinned Wiki Closed Growth-hormone secretagogues and related compounds. Evidence quality here is markedly lower and we say so. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…	+6	10	1.1k	14mo
Why this subcategory is stricter about sourcing than most Compounds › Secretagogues & GH axis observational data tesamorelin needs a source GHRP class Wiki Asking directly, because I could not find a straight answer: Why this subcategory is stricter about sourcing than most Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before posting; the…	+48	52	617	21d
Why pulsatile secretion matters for interpreting secretagogue claims — a second dataset Compounds › Secretagogues & GH axis GHRP class ipamorelin tesamorelin Under review The question in the title: Why pulsatile secretion matters for interpreting secretagogue claims — a second dataset I will give what I have already checked below so nobody repeats it. I have seen LEADER ( N…	+60	64	25k	15mo
IGF-1 as a surrogate endpoint and its limitations Compounds › Secretagogues & GH axis GHRP class needs a source observational data tesamorelin IGF-1 as a surrogate endpoint and its limitations Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I do not…	+5	9	35k	4mo
CJC-1295 with and without DAC: what the modification does — what changed since Compounds › Secretagogues & GH axis GHRP class observational data CJC-1295 tesamorelin CJC-1295 with and without DAC: what the modification does — what changed since Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURMOUNT-OSA ( N Engl J Med , 2024)…		4	5.1k	7mo

Related topics — sharing the tags CJC-1295, observational data, ipamorelin

Topic	Participants	Replies	Views	Activity
Contributing data without breaching anyone's privacy Data & Tools › Datasets data table confounding observational data Solved Contributing data without breaching anyone's privacy Writing it up because I had to work it out twice and would rather nobody else did. I would like to understand what this number means before I repeat it…	+65	71	839	5mo
Revisiting: Oral versus injected administration claims for BPC-157 Compounds › Repair & healing peptides observational data needs a source TB-500 BPC-157 Solved On the subject in the title: Revisiting: Oral versus injected administration claims for BPC-157 Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I…	+23	27	7.7k	15mo
Reading a preclinical wound-healing model and its relevance to a human tendon — a second dataset Compounds › Repair & healing peptides observational data preprint BPC-157 Reading a preclinical wound-healing model and its relevance to a human tendon — a second dataset — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016)…	+64	69	27k	4mo
What would change my mind about repair peptides: a specific answer Compounds › Repair & healing peptides TB-500 needs a source preprint Under review What would change my mind about repair peptides: a specific answer — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 ( JAMA , 2024). Please…	+26	30	1.1k	23h
Research-use-only status: what it means legally and practically — a second dataset Compounds › Other compounds research use only mislabelling needs a source custom synthesis Solved Research-use-only status: what it means legally and practically — a second dataset — setting out what I have, and where I think it stops being reliable. Comparing FLOW ( N Engl J Med , 2024) with SURPASS-2 (…	+109	125	2k	16mo